Whitehawk says Tempus-backed analysis supports SEZ6 as SCLC target for HWK-206 ADC ahead of mid-2026 IND

Whitehawk Therapeutics

Whitehawk Therapeutics

WHWK

0.00
  • Whitehawk Therapeutics announced a real-world market analysis backing SEZ6 as a clinically relevant target in small cell lung cancer, with results presented at ASCO 2026.
  • The analysis found SEZ6 is broadly expressed across small cell lung cancer and other neuroendocrine tumors, supporting its potential as an antibody-drug conjugate target.
  • SEZ6 expression tracked with DLL3, pointing to potential combination strategies with DLL3-directed therapies.
  • The findings support development of HWK-206, with an IND submission expected mid-2026.
  • A Phase 1 study is planned to start in Q3 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605301430PR_NEWS_USPR_____LA71758) on May 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.